

07-24-06

DPM

U.S.P.S. EXPRESS MAIL "POST OFFICE TO ADDRESSEE" SERVICE
DEPOSIT INFORMATION

Express Mail Label No.: EV316035147US

JUL 21 2006 Date of Deposit: July 21, 2006

BRINKS
HOFER
GILSON
& LIONE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Appln. of: John S. Lollar, III

Appln. No.: 10/813,507

Filed: March 30, 2004

For: NUCLEIC ACID AND AMINO ACID
SEQUENCES ENCODING HIGH-LEVEL
EXPRESSOR FACTOR VIII
POLYPEPTIDES AND METHODS OF USE

Attorney Docket No: 13097/3

Examiner: Terra C. Gibbs

Art Unit: 1635

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL

Sir:

Attached is/are:

Transmittal Letter (in dup.); Supplemental Information Disclosure Statement; PTO Form 1449]
 Return Receipt Postcard.

Fee calculation:

No additional fee is required.
 Small Entity.
 An extension fee in an amount of \$____ for a ____-month extension of time under 37 C.F.R. § 1.136(a).
 A petition or processing fee in an amount of \$____ under 37 C.F.R. § 1.17(____).
 An additional filing fee has been calculated as shown below:

	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra	Small Entity		Not a Small Entity	
					Rate	Add'l Fee	or	Rate
Total		Minus			x \$25=			x \$50=
Indep.		Minus			X100=			x \$200=
First Presentation of Multiple Dep. Claim					+\$180=			+\$360=
					Total	\$		Total

Fee payment:

A check in the amount of \$____ is enclosed.
 Please charge Deposit Account No. 23-1925 in the amount of \$____. A copy of this Transmittal is enclosed for this purpose.
 Payment by credit card in the amount of \$____ (Form PTO-2038 is attached).
 The Director is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this paper (including any extension fee required to ensure that this paper is timely filed), or to credit any overpayment, to Deposit Account No. 23-1925.

Respectfully submitted,

C. Noel Kaman

C. Noel Kaman (Reg. No. 51,857)

Date

7/21/06

BRINKS HOFER GILSON & LIONE
NBC Tower – Suite 3600, 455 N. Cityfront Plaza Drive, Chicago, IL 60611-5599

BRINKS
HOFER
GILSON
& LIONE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Appln. of: John S. Lollar, III

Appln. No.: 10/813,507

Filed: March 30, 2004

For: Nucleic Acid and Amino Acid Sequences Encoding High-Level Expressor Factor VIII Polypeptides and Methods of Use

Attorney Docket No: 13097/3

Examiner: Terra C. Gibbs

Art Unit: 1635

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and §§1.97-1.98, and more particularly in accordance with 37 C.F.R. §1.97(c), Applicant hereby cites the following reference(s):

No.	Date of Publication	Patentee/Applicant/Assignee
WO 01/68109 A1	20/September/2001	Lollar, John S.
WO 00/71141 A1	30/November/2000	Lollar, John S.
Other Art:		
	Hemostasis, Thrombosis, and Vascular Biology; "Reduction of the Antigenicity of Factor VIII Toward Complex Inhibitory Antibody Plasmas Using Multiply-Substituted Hybrid Human/Porcine Factor VIII Molecules"; Rachel T. Barrow, John F. Healey, David Gailani, Dorothea Scandella, and Pete Lollar; 2000 by The American Society of Hematology; Blood, 15 January 2000 – Volume 95, Number 2	
	The Journal of Biological Chemistry; "High Level Expression of Recombinant Porcine Coagulation Factor VIII"; Christopher B. Doering, John F. Healey, Ernest T. Parker, Rachel T. Barrow, and Pete Lollar; From the Winship Cancer Institute, Emory University, Atlanta , Georgia; 2002 By The American Society for Biochemistry and Molecular Biology, Inc.; Vol. 277, No. 41, Issue of October 11, pp. 38345-38349, 2002	

Applicant is enclosing Form PTO-1449 (one sheet), along with a copy of each listed reference for which a copy is required under 37 C.F.R. §1.98(a)(2). As each of the listed references is in English, no further commentary is believed to be necessary,

37 C.F.R §1.98(a)(3). Applicant respectfully requests the Examiner's consideration of the above reference(s) and entry thereof into the record of this application.

By submitting this Statement, Applicant is attempting to fully comply with the duty of candor and good faith mandated by 37 C.F.R. §1.56. As such, this Statement is not intended to constitute an admission that any of the enclosed references, or other information referred to therein, constitutes "prior art" or is otherwise "material to patentability," as that phrase is defined in 37 C.F.R. §1.56(a).

Applicant certifies under 37 C.F.R. §1.97(e)(1) that each item of information in this Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement (a copy of any foreign communication first citing a listed reference is attached for the Examiner's reference). Accordingly, Applicant has calculated no fee to be due in connection with the filing of this Statement. However, the Director is authorized to charge any fee deficiency associated with the filing of this Statement to a deposit account, as authorized in the Transmittal accompanying this Statement.

Respectfully submitted,

July 21, 2006

Date


C. Noel Kaman
C. Noel Kaman (Reg. No.51,857)

JUL 21 2006

FORM PTO-1449	SERIAL NO. 10/813,507	CASE NO. 13097/3
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	FILING DATE March 30, 2004	GROUP ART UNIT 1635
(use several sheets if necessary)	APPLICANT(S): John S. Lollar, III	

REFERENCE DESIGNATION **U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER <small>Number-Kind Code (if known)</small>	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
A1	WO 01/68109 A1	20/09/2001	Lollar, John S.		
A2	WO 00/71141 A1	30/11/2000	Lollar, John S.		
A3					
A4					
A5					
A6					
A7					
A8					
A9					
A10					
A11					
A12					
A13					

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER <small>Number-Kind Code (if known)</small>	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES OR NO
A14					
A15					
A16					
A17					
A18					

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)	SERIAL NO. 10/813,507	CASE NO. 13097/3
	FILING DATE March 30, 2004	GROUP ART UNIT 1635
JUL 21 2006	APPLICANT(S): John S. Lollar, III	

EXAMINER INITIAL	OTHER ART – NON PATENT LITERATURE DOCUMENTS (Include name of author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published.)
A19	Hemostasis, Thrombosis, and Vascular Biology; "Reduction of the Antigenicity of Factor VIII Toward Complex Inhibitory Antibody Plasmas Using Multiply-Substituted Hybrid Human/Porcine Factor VIII Molecules"; Rachel T. Barrow, John F. Healey, David Gailani, Dorothea Scandella, and Pete Lollar; 2000 by The American Society of Hematology; Blood, 15 January 2000 – Volume 95, Number 2
A20	The Journal of Biological Chemistry; "High Level Expression of Recombinant Porcine Coagulation Factor VIII"; Christopher B. Doering, John F. Healey, Ernest T. Parker, Rachel T. Barrow, and Pete Lollar; From the Winship Cancer Institute, Emory University, Atlanta , Georgia; 2002 By The American Society for Biochemistry and Molecular Biology, Inc.; Vol. 277, No. 41, Issue of October 11, pp. 38345-38349, 2002
A21	
A22	
A23	
A24	

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.